Treatment of advanced pancreatic cancer with opioid growth factor: Phase I

Anti-Cancer Drugs

Volumn 15, Issue 3, 2004, Pages 203-209

  Smith, Jill P ^a   Conter, Robert L ^a   Bingaman, Sandra I ^a   Harvey, Harold A ^a   Mauger, David T ^a   Ahmad, Mejdi ^a   Demers, Lawrence M ^a   Stanley, Wayne B ^a   McLaughlin, Patricia J ^a   Zagon, Ian S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Adenocarcinoma; Enkephalin; Metastasis; Pancreas

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GROWTH FACTOR; HEMOGLOBIN; OPIOID GROWTH FACTOR; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANIMAL MODEL; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; DRUG SAFETY; DRUG SOLUBILITY; FEMALE; FEVER; HUMAN; HYPOTENSION; MALE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PANCREAS CANCER; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOIMMUNOASSAY; SURVIVAL; VOMITING;

AGED; ANALYSIS OF VARIANCE; FEMALE; GROWTH SUBSTANCES; HUMANS; MALE; MIDDLE AGED; NARCOTICS; PANCREATIC NEOPLASMS; PILOT PROJECTS; RECEPTORS, OPIOID;

EID: 12144288200     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200403000-00003     Document Type: Article

References (37)

1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999; 49:33-64.
2. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53:5-26.
3. Bramhall S, Dunn JA, Neoptolemos JP. Epidemiology of pancreatic cancer. In: Berger HG, Warshaw AL, Buchler MW, Carr-Locke DL, Neoptolemos JP, Russell C, et al. (editors): The Pancreas. Boston, MA: Blackwell Science; 1998, pp. 889-906.
4. McGinn CJ, Lawrence TS, Zalupski MM. On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer. Cancer 2002; 95:933-940.
5. Oettle H, Riess H. Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer. Cancer 2002; 95:912-922.
6. Heinemann V. Gemcitabine-based combination treatment of pancreatic cancer. Semin Oncol 2002; 29:25-35.
7. Blackstock AW, Bernard SA, Richards F, Eagle KS, Case LD, Poole ME, et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 1999; 17: 2208-2212.
8. Wolff RA. Novel therapies for pancreatic cancer. Cancer J 2001; 7: 349-358.
9. Ozawa F, Friess H, Tempia-Caliera A, Kleeff J, Buchler MW. Growth factors and their receptors in pancreatic cancer. Teratog Carcinog Mutagen 2001; 21:27-44.
10. Reddy SA. Signaling pathways in pancreatic cancer. Cancer J 2001; 7:274-286.
11. Shi X, Friess H, Kleeff J, Ozawa F, Buchler MW. Pancreatic cancer: factors regulating tumor development, maintenance and metastasis. Pancreatology 2001; 1:517-624.
12. Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Rev 2002; 38:351-376.
13. Zagon IS, Smith JP, McLaughlin PJ. Human pancreatic cancer cell proliferation in tissue culture is tonically inhibited by opioid growth factor. Int J Oncol 1999; 14:577-584.
14. Zagon IS, Smith JP, Conter R, McLaughlin PJ. Identification and characterization of opioid growth factor receptor in human pancreatic adenocarcinoma. Int J Mol Med 2000; 5:77-84.
15. Zagon IS, Hytrek SD, Smith JP, McLaughlin PJ. Opioid growth factor (OGF) inhibits human pancreatic cancer transplanted into nude mice. Cancer Lett 1997; 112:167-175.
16. Zagon IS, Roesener CD, Verderame MF, Ohlsson-Wilhelm BM, Levin RJ, McLaughlin PJ. Opioid growth factor regulates the cell cycle of human neoplasias. Int J Oncol 2000; 17:1053-1061.
17. Zagon IS, Ruth TB, Leure-duPree AE, Sassani JW, McLaughlin PJ. Immunoelectron microscopic localization of the opioid growth factor receptor (OGFr) and OGF in the cornea. Brain Res 2003; 967:37-47.
18. Karnofsky DA, Abelmann WH, Graver LF, Burchenal JH. Performance status in cancer patients. Cancer 1948; 1:634-656.
19. NCI. Cancer Therapy Evaluation Program: Common Toxicity Criteria. Version 2.0 DCTD. Bethesda, MD: NCI, NIH; 1998.
20. Bergner M. Development, testing, and the use of the Sickness Impact Profile. In: Walker SR, Rosser RM (editors): Qualify of Life: Assessment and Application. Boston, MA: MTP Press; 1987, pp. 70-94.
21. Beck AT, Ward CH, Medelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiat 1961; 4:561-571.
22. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975; 1:277-299.
23. Smith JP, Conter RL, Demers LM, McLaughlin PJ, Zagon IS. Elevated levels of opioid growth factor in the plasma of patients with pancreatic cancer. Pancreas 2000; 21:158-164.
24. Duthie DJ, Nimmo WS. Adverse effects of opioid analgesic drugs. Br J Anaesth 1987; 59:61-77.
25. Green MR. Gemcitabine safety overview. Semin Oncol 1996; 23:32-35.
26. Storniolo AM, Allerheiligen SR, Pearce HL. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 1997; 24:S7.
27. Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 1998; 34:39-43.
28. Mitchelson F. Pharmacological agents affecting emesis. A review (Part I). Drugs 1992; 43:295-315.
29. Vogelzang NJ. Nephrotoxicity from chemotherapy: prevention and management. Oncology (Huntingt) 1991; 5:97-102, 105.
30. Shakin EJ, Holland J. Depression and pancreatic cancer. J Pain Symptom Manage 1988; 3:194-198.
31. Bridenbaugh LD, Moore DC, Campbell DD. Management of upper abdominal cancer pain: treatment with celiac plexus block with alcohol. J Am Med Ass 1964; 190:99-102.
32. Burris HA, III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-2413.
33. Burris H, Storniolo AM. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 1997; 33(suppl 1):S18-S22.
34. McLaughlin PJ, Levin RJ, Zagon IS. Regulation of human head and neck squamous cell carcinoma growth in tissue culture by opioid growth factor. Int J Oncol 1999; 14:991-998.
35. 5]enkephalin) prevents the incidence and retards the growth of human colon cancer. Am J Physiol 1996; 271:R780-R786.
36. Bisignani GJ, McLaughlin PJ, Ordille SD, Beltz MS, Jarowenko MV, Zagon IS. Human renal cell proliferation in tissue culture is tonically inhibited by opioid growth factor. J Urol 1999; 162:2186-2191.
37. McLaughlin PJ, Zagon IS, Skitzki J. Human neuroblastoma cell growth in tissue culture is regulated by opioid growth factor. Int J Oncol 1999; 14:373-383.